Payment overview · 2025
General Payments
$609.19
26 reported records · 16 companies
Healthcare provider profile · identity verified
Pui-Sum Susan Wong, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TEXARKANA, TX · NPI 1912975111
Verified facts
What the public records show
CMS Open Payments records show Pui-Sum Susan Wong, M.D. received $609.19 in general payments during 2025 across 26 reported records.
Lilly USA, LLC accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 321 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xtandi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $189.02 | 31.0% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $70.61 | 11.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $63.78 | 10.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.74 | 8.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.32 | 5.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.55 | 5.2% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $24.50 | 4.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.78 | 3.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.65 | 3.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.08 | 2.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.03 | 2.6% | 1 | 2025 |
| EVOKE PHARMA, INC. | Unresolved — no canonical attribution shown | $14.71 | 2.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.61 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.58 | 2.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.22 | 2.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.01 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $609.19 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $109.63 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $86.43 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $70.61 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $63.78 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.74 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $49.35 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.32 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| GIMOTI Normalized: gimoti |
Drug | EVOKE PHARMA, INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.01 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 327 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 321 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
129 | 34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 29 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
327 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
140 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
321 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
174 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
76 | 76 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
327 | 67 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 1294 | 333 |
| Amlodipine Besylate | Amlodipine Besylate | 1287 | 338 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1147 | 324 |
| Atorvastatin Calcium | Atorvastatin Calcium | 996 | 265 |
| Levothyroxine Sodium | Levothyroxine Sodium | 848 | 215 |
| Metoprolol Succinate | Metoprolol Succinate | 727 | 174 |
| Gabapentin | Gabapentin | 712 | 200 |
| Omeprazole | Omeprazole | 697 | 176 |
| Potassium Chloride | Potassium Chloride | 658 | 198 |
| Pantoprazole Sodium | Pantoprazole Sodium | 557 | 151 |
| Furosemide | Furosemide | 472 | 136 |
| Hydrochlorothiazide | Hydrochlorothiazide | 360 | 107 |
| Eliquis | Apixaban | 327 | 67 |
| Mounjaro | Tirzepatide | 321 | 53 |
| Lisinopril | Lisinopril | 303 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 300 | 77 |
| Spironolactone | Spironolactone | 292 | 77 |
| Ezetimibe | Ezetimibe | 280 | 92 |
| Pravastatin Sodium | Pravastatin Sodium | 277 | 79 |
| Glimepiride | Glimepiride | 259 | 71 |
| Hydralazine Hcl | Hydralazine Hcl | 244 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 236 | 36 |
| Atenolol | Atenolol | 211 | 56 |
| Metformin Hcl Er | Metformin Hcl | 208 | 64 |
| Montelukast Sodium | Montelukast Sodium | 208 | 52 |
| Carvedilol | Carvedilol | 207 | 60 |
| Sertraline Hcl | Sertraline Hcl | 205 | 48 |
| Alendronate Sodium | Alendronate Sodium | 201 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 197 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 54 |
| Meloxicam | Meloxicam | 191 | 54 |
| Farxiga | Dapagliflozin Propanediol | 183 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 178 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 46 |
| Trazodone Hcl | Trazodone Hcl | 177 | 47 |
| Bupropion Xl | Bupropion Hcl | 174 | 39 |
| Ozempic | Semaglutide | 174 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 36 |
| Valsartan | Valsartan | 149 | 37 |
| Tramadol Hcl | Tramadol Hcl | 145 | 37 |
| Allopurinol | Allopurinol | 141 | 38 |
| Jardiance | Empagliflozin | 140 | 29 |
| Famotidine | Famotidine | 138 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 133 | 36 |
| Synthroid | Levothyroxine Sodium | 129 | 34 |
| Pregabalin | Pregabalin | 127 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 35 |
| Clonazepam | Clonazepam | 110 | 16 |
| Donepezil Hcl | Donepezil Hcl | 105 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 102 | 25 |
| Metformin Hcl | Metformin Hcl | 101 | 27 |
| Alprazolam | Alprazolam | 98 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 26 |
| Mirtazapine | Mirtazapine | 95 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 95 | 60 |
| Ibandronate Sodium | Ibandronate Sodium | 94 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 22 |
| Memantine Hcl | Memantine Hcl | 90 | 20 |
| Temazepam | Temazepam | 90 | 13 |
| Celecoxib | Celecoxib | 88 | 26 |
| Lorazepam | Lorazepam | 88 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 77 | 21 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 76 | 76 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 18 |
| Klor-Con M20 | Potassium Chloride | 72 | 32 |
| Simvastatin | Simvastatin | 72 | 21 |
| Clonidine Hcl | Clonidine Hcl | 71 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 17 |
| Chlorthalidone | Chlorthalidone | 65 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 20 |
| Telmisartan | Telmisartan | 65 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 61 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 26 |
| Methocarbamol | Methocarbamol | 58 | 20 |
| Eszopiclone | Eszopiclone | 57 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 57 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 56 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 27 |
| Prednisone | Prednisone | 52 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 13 |
| Irbesartan | Irbesartan | 50 | 15 |
| Novolog Flexpen | Insulin Aspart | 47 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | 14 |
| Torsemide | Torsemide | 43 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 15 |
| Linzess | Linaclotide | 42 | 15 |
| Propranolol Hcl | Propranolol Hcl | 42 | 15 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 39 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Nifedipine Er | Nifedipine | 37 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 37 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 36 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 13 |
| Pitavastatin Calcium | Pitavastatin Calcium | 33 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Finasteride | Finasteride | 30 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Azithromycin | Azithromycin | 28 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 24 |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 22 |
| Clonidine | Clonidine | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 21 |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Xtandi | Enzalutamide | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $609.19 · 26 records | Lilly USA, LLC | CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, GIMOTI, IBSRELA, Korlym, LEQVIO, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OFEV, OTEZLA, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error